1. | charlie4500kelly | |
2. | bcavage | |
3. | falkev01 | |
4. | geocansan | |
5. | DontGiveMeLip |
1. | charlie4500kelly | |
2. | bcavage | |
3. | falkev01 | |
4. | geocansan | |
5. | DontGiveMeLip |
1. | bcavage 07/17/2018 Enters strategic alliance with Tasly Pharmaceutical Group; will receive $40 mln on closing |
2. | geocansan 08/30/2018 Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group |
3. | charlie4500kelly 05/31/2018 Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 |
4. | bcavage 05/29/2018 Mesoblast Partners With Cartherics to Develop 'off-the-shelf' Cell-based Immunotherapies for Solid Cancers |
5. | falkev01 04/19/2018 Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure |
6. | falkev01 02/21/2018 Big moves ahead |
7. | DontGiveMeLip 06/07/2018 H.C. Wainwright & Co. initiates coverage with Buy rating, $17 PT |
8. | charlie4500kelly 02/21/2018 OK let's see what happens now...... |
9. | charlie4500kelly 03/29/2018 Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment |
10. | charlie4500kelly 10/02/2018 Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions |